Get the Stockscreener App
0.9725
2.91%
0.0275
Lava Therapeutics Nv stock is traded at $0.9725, with a volume of 3,136.
It is up +2.91% in the last 24 hours and down -9.95% over the past month.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
See More
Previous Close:
$0.945
Open:
$0.9677
24h Volume:
3,136
Relative Volume:
0.03
Market Cap:
$24.85M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-0.5065
EPS:
-1.92
Net Cash Flow:
$5.89M
1W Performance:
-0.77%
1M Performance:
-9.95%
6M Performance:
-44.43%
1Y Performance:
-41.42%
1-Day Range:
$0.958
$0.98
1-Week Range:
$0.93
$1.03
52-Week Range:
$0.8807
$6.47
Lava Therapeutics Nv Stock (LVTX) Company Profile
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
0.9725 | 24.85M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.97 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.04 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.65 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.27 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.22 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
LAVA Therapeutics begins trial for cancer treatment - Investing.com India
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire
LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan
LAVA Therapeutics begins trial for cancer treatment By Investing.com - Investing.com Nigeria
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World
LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com
LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com
Lava Therapeutics' SWOT analysis: stock faces challenges after key asset discontinuation - Investing.com
Research Analysts Issue Forecasts for LVTX Q1 Earnings - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
Leerink cuts Lava Therapeutics stcok to Market Perform By Investing.com - Investing.com Nigeria
Leerink cuts Lava Therapeutics stcok to Market Perform - Investing.com India
JMP Securities Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
LAVA Therapeutics stock hits 52-week low at $1.35 - Investing.com
Lava Therapeutics' SWOT analysis: biotech stock shows promise amid challenges - Investing.com Nigeria
LAVA Reports Third Quarter 2024 Financial Results and - GlobeNewswire
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 - The Manila Times
LAVA Therapeutics (NASDAQ:LVTX) Trading Down 5.6% – Time to Sell? - Defense World
Some Major Key Players In The RNA Editing Market: - InsightAce Analytic
Lava Therapeutics' SWOT analysis: oncology biotech's stock potential amid trials - Investing.com UK
Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua
After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK
LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results - Defense World
LAVA Therapeutics Faces Financial Hurdles - TipRanks
LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
LAVA Therapeutics NV expected to post a loss of 36 cents a shareEarnings Preview - XM
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 2.3% - Defense World
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy - Yahoo Finance Australia
LAVA Therapeutics (NASDAQ:LVTX) Shares Down 0.7% - American Banking and Market News
Lava Therapeutics shares hold target with Buy rating - Investing.com India
LAVA Therapeutics Shareholders Approve Key Resolutions - TipRanks
LAVA Announces Annual Meeting of Shareholders - GlobeNewswire
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com Australia
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive - Simply Wall St
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference - Yahoo Finance
LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint - Yahoo Finance
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results - GlobeNewswire
LAVA Announces Clinical Development Milestone Achieved by - GlobeNewswire
LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):